Quent Capital LLC Sells 39 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Quent Capital LLC lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,765 shares of the medical research company’s stock after selling 39 shares during the quarter. Quent Capital LLC’s holdings in Thermo Fisher Scientific were worth $921,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Silicon Valley Capital Partners bought a new stake in Thermo Fisher Scientific in the 1st quarter valued at about $29,000. OLD Mission Capital LLC bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $31,000. Live Oak Investment Partners acquired a new position in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $36,000. Grey Fox Wealth Advisors LLC bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth $43,000. Finally, Barrett & Company Inc. bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at $43,000. Institutional investors and hedge funds own 87.06% of the company’s stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $0.11 on Friday, reaching $515.53. 5,179,741 shares of the company’s stock were exchanged, compared to its average volume of 1,216,868. The firm has a market cap of $198.97 billion, a price-to-earnings ratio of 35.24, a P/E/G ratio of 2.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.02. The stock has a fifty day simple moving average of $540.34 and a 200-day simple moving average of $541.69. Thermo Fisher Scientific Inc. has a 52 week low of $475.77 and a 52 week high of $609.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.43 by ($0.28). The business had revenue of $10.69 billion for the quarter, compared to the consensus estimate of $10.99 billion. Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The company’s revenue was down 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $5.51 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 15th will be paid a dividend of $0.35 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $1.40 annualized dividend and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.57%.

Analysts Set New Price Targets

TMO has been the subject of several recent research reports. KeyCorp decreased their target price on shares of Thermo Fisher Scientific from $710.00 to $640.00 in a research report on Thursday, May 25th. Robert W. Baird lowered their price objective on Thermo Fisher Scientific from $664.00 to $625.00 and set an “outperform” rating for the company in a research note on Thursday, July 27th. Barclays lifted their target price on Thermo Fisher Scientific from $590.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, July 27th. Raymond James raised their price objective on Thermo Fisher Scientific from $595.00 to $630.00 and gave the company an “outperform” rating in a research note on Friday, July 28th. Finally, Royal Bank of Canada increased their target price on shares of Thermo Fisher Scientific from $662.00 to $698.00 in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $631.71.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 14,100 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $550.00, for a total value of $7,755,000.00. Following the sale, the chief financial officer now owns 27,393 shares in the company, valued at $15,066,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CFO Stephen Williamson sold 14,100 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $550.00, for a total value of $7,755,000.00. Following the transaction, the chief financial officer now directly owns 27,393 shares in the company, valued at $15,066,150. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total transaction of $5,490,000.00. Following the completion of the transaction, the chief executive officer now directly owns 141,330 shares of the company’s stock, valued at approximately $77,590,170. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock valued at $15,799,270 in the last three months. Company insiders own 0.32% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.